Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-04-15
2003-05-06
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S042000, C549S358000, C514S453000
Reexamination Certificate
active
06559177
ABSTRACT:
This invention relates to 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones which are useful as estrogenic agents.
The pleiotropic effects of estrogens in mammalian tissues have been well documented. (Dey, M.; Lyttle, C. R.; Pickar, J. H.
Maturitas
(2000), 34(S2), S25-S33. Speroff, L
Ann. N. Y. Acad. Sci
. (2000), 900, 26-39. Nozaki, M. Ernst Schering Res. Found. Workshop (2000), Suppl. 4, 115-125). The estrogen receptor (ER), a member of the nuclear hormone receptor family, regulates transcription through its interactions with a large number of proteins including co-activators and co-repressors (collectively referred to as coregulators) and an estrogen response element (ERE). In addition to its ability to effect the cellular transcription machinery through the ERE, ER can also affect transcriptional processes independent of its direct interaction with DNA. For example, it has been demonstrated that 17&bgr;-estradiol can inhibit IL-6 promoter activity. This inhibition requires 17&bgr;-estradiol binding to the receptor, but does not depend on having a functional DNA-binding domain (Ray, A.; Prefontaine, K. E.; Ray, P. J.
J. Biol. Chem.,
1994, 269, 12940). Even the unliganded receptor may affect the transcription process after phosphorylation of serine residues, especially in the AF-1 containing AB domains of the receptor.
Recently, a second ER receptor (ER&bgr;) with high affinity for 17&bgr;-estradiol has been identified. A comparison of the physical structure of ER&bgr; with the first to be identified estrogen receptor (ER&agr;) reveals that ER&bgr; is shorter in length (530 AA vs. 595 AA) but contains the same functional domains although the AB domains of ER&bgr; are somewhat truncated relative to ER&agr; (148AA vs. 180AA) and not surprisingly, the AF-1 activation potential between the two receptors is different (McInerney, Eileen M.; Weis, Karen E.; Sun, Jun; Mosselman, Sietse; Katzenellenbogen, Benita S.
Endocrinology
(1998), 139(11), 4513-4522). The C domain (DNA-binding domain) displays remarkable homology between the two receptors (96%) and a fortiori, the two receptors would be expected to bind with similar affinities to a given ERE. However, although it has been shown that the two receptors bind to ERE's vitogenellin, c-fos, c-jun, pS2, cathepsin D, and acetylcholine transferase, they do not necessarily bind with the same affinity (Hyder, S. M., Chiappefta, C., Stancel, G. M.
Biochem. Pharmacol
. (1999), 57, 597-601). In contrast, the E domain (ligand binding domain or LBD) of the two receptors share only a 60% homology. However, structural analyses of the two receptors indicates that the residues in the ligand contact area are very similar, with only two residues different (ER&agr; 421(Met) ER&bgr; 373(Ile); ER&agr; 384 (Leu) ER&bgr; 336(Met)). Additionally, the variations in the overall sequence of the two receptors may also lead to different interactions between the subtypes and the various coregulatory proteins that enable or modify the ER transcriptional machinery. In fact, preliminary studies suggest that the coregulator SRC-3 interacts to a much greater extent with ER&agr; than with ER&bgr; (Suen, Chen-Shian; Berrodin, Thomas J.; Mastroeni, Robert; Cheskis, Boris J.; Lyttle, C. Richard; Frail, Donald
J. Biol. Chem
. (1998), 273(42), 27645-27653).
Besides the differential interaction of the two receptors with various coregulatory proteins, the two receptors also have tissue distribution that is not coextensive. Even within a given tissue where both receptors are coexpressed there is sometimes localization of one of the receptors in a given cell-type. For example, in the human ovary, both ER&agr; and ER&bgr; RNA expression can be detected. Immunostaining demonstrates that ER&bgr; is present in multiple cell types including granulosa cells in small, medium and large follicles, theca and corpora lutea, whereas ER&agr; was weakly expressed in the nuclei of granulosa cells, but not in the theca nor in the corpora lutea (Taylor, A. H.; Al-Azzawi, F.
J. Mol. Endocrinol.
(2000), 24(1), 145-155). In the endometrium, immunostaining showed both ER&agr; and ER&bgr; in luminal epithelial cells and in the nuclei of stromal cells but, significantly, ER&bgr; appears to be weak or absent from endometrial glandular epithelia (Taylor, et al). Epithelial cells in most male tissues including the prostate, the urothelium and muscle layers of the bladder, and Sertoli cells in the testis, are also immunopositive for ER&bgr;. Significant ER&bgr; immunoreactivity has been detected in most areas of the brain, with the exception of the hippocampus, a tissue that stained positive for only ER&agr;, ibid.
Estrogens have been shown to exert a positive effect on the cardiovascular system that may help to explain the increased risk of cardiovascular disease observed in the post-menopause period. While some of the cardiovascular benefit may occur through estrogen action on the liver via upregulation of the LDL receptor (thus decreasing LDL levels, presumably an ER&agr; mediated response), it is also likely that direct action on the arterial wall also has a role. It has been demonstrated that after a vascular injury event (denudation of rat artery), ER&bgr; message in the endothelial cells is upregulated by as much as 40 times that of ER&agr; (Makela, Sari; Savolainen, Hanna; Aavik, Einari; Myllarniemi, Marjukka; Strauss, Leena; Taskinen, Eero; Gustafsson, Jan-Ake; Hayry, Pekka. (1999), 96(12), 7077-7082). In addition, 17&bgr;-estradiol was able to inhibit the vascular injury response in an ER&agr; knockout mouse, although this same response was also inhibited in an ER&bgr; knockout mouse (Iafrati, Mark D.; Karas, Richard H.; Aronovitz, Mark; Kim, Sung; Sullivan, Theodore R., Jr.; Lubahn, Dennis B.; O'Donnell, Thomas F., Jr.; Korach, Kenneth S.; Mendelsohn, Michael E.
Nat. Med
. (N.Y.) (1997), 3(5), 545-548. Karas, Richard H.; Hodgin, Jeffrey B.; Kwoun, Moon; Krege, John H.; Aronovitz, Mark; Mackey, William; Gustafsson, Jan Ake; Korach, Kenneth S.; Smithies, Oliver; Mendelsohn, Michael E.
Proc. Natl. Acad. Sci. U.S.A
. (1999), 96(26), 15133-15136). Provided that the response is not being inhibited by a yet unidentified estrogen receptor, it is likely that the injury response could be inhibited by ligands that are selective for either one of the two receptors.
When the typical estrogen binds with an ER receptor, the receptor dissociates from HSP 90 as well as other molecular chaperones, and dimerizes with another receptor. Since this mechanism of activation is shared by both ER receptors, the possibility exists for heterodimerization to take place in tissues where both receptors are expressed. Indeed, heterodimers of ER&agr; and ER&bgr; bind DNA with an affinity equal to that of ER&agr; homodimers and greater than ER&bgr; homodimers (Cowley, Shaun M.; Hoare, Susan; Mosselman, Sietse; Parker, Malcolm G.
J. Biol. Chem
. (1997), 272(32), 19858-19862).
REFERENCES:
patent: 5424331 (1995-06-01), Shlyankevich
patent: 5516528 (1996-05-01), Hughes et al.
patent: 5523087 (1996-06-01), Shlyankevich
patent: 5952374 (1999-09-01), Clarkson, Jr. et al.
patent: 6331562 (2001-12-01), Bhagwat et al.
patent: 195 24 937 (1997-01-01), None
patent: 196 54 750 (1998-07-01), None
patent: 0 993 781 (2000-04-01), None
patent: 1 060 744 (2000-12-01), None
patent: WO 98/03180 (1998-01-01), None
patent: WO 98/21946 (1998-05-01), None
patent: WO 98/26784 (1998-06-01), None
patent: WO 98/29129 (1998-07-01), None
patent: WO 98/56812 (1998-12-01), None
patent: WO 99/17767 (1999-04-01), None
patent: WO 00/30663 (2000-06-01), None
patent: WO 00/30664 (2000-06-01), None
patent: WO 00/62765 (2000-10-01), None
Miller et al; Dec. 2001; Elsevier Science Ltd., Tetrahedron Letters, vol. 42, p. 8429-8431.*
Klaus Goerlitzer; 1976; Weinheim, German; Arch. Pharm. 309(1), p. 18-25.*
Klaus Goerlitzer, “1,3-Dicarbonyl compounds. 2. Benz[b]indeno[2, 1-e]pyran-4-one”; 1975; CA 84:17074.*
Gilbert Nepault; “New synthesis of a benzofurano[2,3:3′,2&P
Collini Michael D.
Harris Heather A.
Keith, Jr. James C.
Miller Christopher P.
McKane Joseph K.
Milowsky Arnold S.
Shiao Robert
Wyeth
LandOfFree
5, 11-Dioxa-benzo[b]fluoren-10-one and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5, 11-Dioxa-benzo[b]fluoren-10-one and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5, 11-Dioxa-benzo[b]fluoren-10-one and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3021700